Tirzepatide for Heart Health: What the Evidence Shows
What human and animal studies show about Tirzepatide for heart health, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 358
- PubMed records, our ledger
- Animal studies
- 11
- PubMed records, our ledger
- Studies we summarised
- 7
- with an outcome for heart health
Evidence for heart health
Each row is an outcome related to heart health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Cardiovascular death, MI or stroke | Primary events occurred in 12.2% (tirzepatide) vs 13.1% (dulaglutide); hazard ratio 0.92 (95.3% CI 0.83 to 1.01), noninferior but superiority not shown (P = 0.09). | Human RCTn = 13165 | The New England journal of medicine 2025, PMID 41406444 |
| Cardiovascular death or worsening heart failure | The composite occurred in 9.9% on tirzepatide vs 15.3% on placebo (hazard ratio 0.62, 95% CI 0.41 to 0.95). | Human RCTn = 731 | The New England journal of medicine 2025, PMID 39555826 |
| Quality of life (KCCQ-CSS) | The symptom score improved by 19.5 with tirzepatide vs 12.7 with placebo, a difference of 6.9 (95% CI 3.3 to 10.6). | Human RCTn = 731 | The New England journal of medicine 2025, PMID 39555826 |
| Blood pressure | By 72 weeks, blood pressure was 6.8 mm Hg systolic and 4.2 mm Hg diastolic lower than with placebo. | Human RCT | Heart 2024, PMID 39084707 |
| Role of weight loss | Weight loss explained 68% of the systolic and 71% of the diastolic blood pressure reduction. | Human RCT | Heart 2024, PMID 39084707 |
| Triglycerides and metabolites | Triglycerides and diglycerides were lowered significantly versus baseline, dulaglutide and placebo (post hoc analysis). | Human RCTn = 259 | The Journal of clinical endocrinology and metabolism 2022, PMID 34608929 |
| Major adverse cardiovascular events | MACE-4 events were not increased on tirzepatide versus glargine (hazard ratio 0·74, 95% CI 0·51-1·08). | Human RCTn = 1995 | Lancet 2021, PMID 34672967 |
| Systolic blood pressure | Systolic blood pressure fell by a median of 4.20 (5 mg), 5.34 (10 mg) and 5.77 mmHg (15 mg). | Meta-analysis | Diabetes, obesity & metabolism 2023, PMID 37700437 |
| Total cholesterol | Total cholesterol fell by a median of 3.76% (5 mg), 4.63% (10 mg) and 5.93% (15 mg). | Meta-analysis | Diabetes, obesity & metabolism 2023, PMID 37700437 |
| Lipid fractions | Tirzepatide raised HDL cholesterol and lowered LDL cholesterol and triglycerides. | Meta-analysis | Diabetes, obesity & metabolism 2023, PMID 37700437 |
| Major adverse cardiovascular events | Hazard ratios versus controls were 0.80 (95% CI 0.57-1.11) for the four-component cardiovascular composite, 0.90 for cardiovascular death and 0.80 for all-cause death; none were statistically significant. | Meta-analysis | Nature medicine 2022, PMID 35210595 |
PubMed records for Tirzepatide and heart health: 358 human, 11 animal (search counts, not studies we reviewed). Grades follow our evidence scale.
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Other peptides people research for heart health
All peptides for heart health, comparedCommon questions
Does Tirzepatide help with heart health?
The strongest study we summarise for heart health is human rct evidence, across 7 studies with an outcome for heart health. A trial result is not an approval; see the legal status.
Is Tirzepatide approved for heart health?
Tirzepatide is FDA approved (Mounjaro, Zepbound). Which conditions that approval covers is set by the label; use for anything else is off-label.
What is the best peptide for heart health?
There is no single answer. Our heart health overview compares each candidate by evidence grade and legal status rather than by popularity.
More on Tirzepatide
Sources
- 1Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine · 2025PMID 41406444Accessed 2 Oct 2026
- 2Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.The New England journal of medicine · 2025PMID 39555826Accessed 2 Oct 2026
- 3Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.Heart (British Cardiac Society) · 2024PMID 39084707Accessed 2 Oct 2026
- 4Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2022PMID 34608929Accessed 2 Oct 2026
- 5Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.Lancet (London, England) · 2021PMID 34672967Accessed 2 Oct 2026
- 6Effect of tirzepatide on blood pressure and lipids: A meta-analysis of randomized controlled trials.Diabetes, obesity & metabolism · 2023PMID 37700437Accessed 2 Oct 2026
- 7Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.Nature medicine · 2022PMID 35210595Accessed 2 Oct 2026
Found an error? Report a correction.